 | • レポートコード：QYR2104Z2803 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、HER2陽性乳がんのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（グリフォラフロンドサ、手術、放射線・化学療法、内分泌療法、分子標的療法）、用途別市場規模（病院、専門クリニック、バイオテクノロジー・製薬会社、研究機関・学術機関、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・HER2陽性乳がんの市場動向 ・企業の競争状況、市場シェア ・HER2陽性乳がんの種類別市場規模（グリフォラフロンドサ、手術、放射線・化学療法、内分泌療法、分子標的療法） ・HER2陽性乳がんの用途別市場規模（病院、専門クリニック、バイオテクノロジー・製薬会社、研究機関・学術機関、その他） ・HER2陽性乳がんの北米市場規模2016-2027（アメリカ、カナダ） ・HER2陽性乳がんのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・HER2陽性乳がんのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・HER2陽性乳がんの中南米市場規模2016-2027（メキシコ、ブラジル） ・HER2陽性乳がんの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer (Pharmacia and Upjohn Company)、Novartis、AstraZeneca Pharmaceuticals、Eli Lilly、Roche Group、Merck、Jiangsu HengRui Medicine、Odonate Therapeutics、Radius Pharmaceuticals、Immunomedics、Syndax Pharmaceuticals、Bayer、Eagle Pharmaceuticals、Merrimack Pharmaceuticals、GlaxoSmithKline、Millennium Pharmaceuticals） ・結論 |
HER2, also known as human epidermal growth factor receptor 2, is an important prognostic factor for breast cancer.HER2 is also expressed on the surface of some normal cells in the body.Her2-positive breast cancer is characterized by strong invasion, more recurrence and metastasis, and short disease-free survival.
Market Analysis and Insights: Global HER2-Positive Breast Cancer Market
The global HER2-Positive Breast Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global HER2-Positive Breast Cancer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global HER2-Positive Breast Cancer market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global HER2-Positive Breast Cancer market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global HER2-Positive Breast Cancer market.
Global HER2-Positive Breast Cancer Scope and Market Size
HER2-Positive Breast Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global HER2-Positive Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Grifola Frondosa
Surgery
Radiation and Chemotherapy
Endocrine Therapy
Molecular Targeted Therapy
Segment by Application
Hospital
Specialist Clinic
Biotechnology and Pharmaceutical Companies
Research and Academic Institutions
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer (Pharmacia and Upjohn Company)
Novartis
AstraZeneca Pharmaceuticals
Eli Lilly
Roche Group
Merck
Jiangsu HengRui Medicine
Odonate Therapeutics
Radius Pharmaceuticals
Eli Lilly
Roche Group
Bayer
Eagle Pharmaceuticals
Merrimack Pharmaceuticals
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HER2-Positive Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Grifola Frondosa
1.2.3 Surgery
1.2.4 Radiation and Chemotherapy
1.2.5 Endocrine Therapy
1.2.6 Molecular Targeted Therapy
1.3 Market by Application
1.3.1 Global HER2-Positive Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Biotechnology and Pharmaceutical Companies
1.3.5 Research and Academic Institutions
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global HER2-Positive Breast Cancer Market Perspective (2016-2027)
2.2 HER2-Positive Breast Cancer Growth Trends by Regions
2.2.1 HER2-Positive Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 HER2-Positive Breast Cancer Historic Market Share by Regions (2016-2021)
2.2.3 HER2-Positive Breast Cancer Forecasted Market Size by Regions (2022-2027)
2.3 HER2-Positive Breast Cancer Industry Dynamic
2.3.1 HER2-Positive Breast Cancer Market Trends
2.3.2 HER2-Positive Breast Cancer Market Drivers
2.3.3 HER2-Positive Breast Cancer Market Challenges
2.3.4 HER2-Positive Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HER2-Positive Breast Cancer Players by Revenue
3.1.1 Global Top HER2-Positive Breast Cancer Players by Revenue (2016-2021)
3.1.2 Global HER2-Positive Breast Cancer Revenue Market Share by Players (2016-2021)
3.2 Global HER2-Positive Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by HER2-Positive Breast Cancer Revenue
3.4 Global HER2-Positive Breast Cancer Market Concentration Ratio
3.4.1 Global HER2-Positive Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HER2-Positive Breast Cancer Revenue in 2020
3.5 HER2-Positive Breast Cancer Key Players Head office and Area Served
3.6 Key Players HER2-Positive Breast Cancer Product Solution and Service
3.7 Date of Enter into HER2-Positive Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HER2-Positive Breast Cancer Breakdown Data by Type
4.1 Global HER2-Positive Breast Cancer Historic Market Size by Type (2016-2021)
4.2 Global HER2-Positive Breast Cancer Forecasted Market Size by Type (2022-2027)
5 HER2-Positive Breast Cancer Breakdown Data by Application
5.1 Global HER2-Positive Breast Cancer Historic Market Size by Application (2016-2021)
5.2 Global HER2-Positive Breast Cancer Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America HER2-Positive Breast Cancer Market Size (2016-2027)
6.2 North America HER2-Positive Breast Cancer Market Size by Type
6.2.1 North America HER2-Positive Breast Cancer Market Size by Type (2016-2021)
6.2.2 North America HER2-Positive Breast Cancer Market Size by Type (2022-2027)
6.2.3 North America HER2-Positive Breast Cancer Market Size by Type (2016-2027)
6.3 North America HER2-Positive Breast Cancer Market Size by Application
6.3.1 North America HER2-Positive Breast Cancer Market Size by Application (2016-2021)
6.3.2 North America HER2-Positive Breast Cancer Market Size by Application (2022-2027)
6.3.3 North America HER2-Positive Breast Cancer Market Size by Application (2016-2027)
6.4 North America HER2-Positive Breast Cancer Market Size by Country
6.4.1 North America HER2-Positive Breast Cancer Market Size by Country (2016-2021)
6.4.2 North America HER2-Positive Breast Cancer Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe HER2-Positive Breast Cancer Market Size (2016-2027)
7.2 Europe HER2-Positive Breast Cancer Market Size by Type
7.2.1 Europe HER2-Positive Breast Cancer Market Size by Type (2016-2021)
7.2.2 Europe HER2-Positive Breast Cancer Market Size by Type (2022-2027)
7.2.3 Europe HER2-Positive Breast Cancer Market Size by Type (2016-2027)
7.3 Europe HER2-Positive Breast Cancer Market Size by Application
7.3.1 Europe HER2-Positive Breast Cancer Market Size by Application (2016-2021)
7.3.2 Europe HER2-Positive Breast Cancer Market Size by Application (2022-2027)
7.3.3 Europe HER2-Positive Breast Cancer Market Size by Application (2016-2027)
7.4 Europe HER2-Positive Breast Cancer Market Size by Country
7.4.1 Europe HER2-Positive Breast Cancer Market Size by Country (2016-2021)
7.4.2 Europe HER2-Positive Breast Cancer Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific HER2-Positive Breast Cancer Market Size (2016-2027)
8.2 Asia-Pacific HER2-Positive Breast Cancer Market Size by Type
8.2.1 Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2016-2021)
8.2.2 Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2022-2027)
8.2.3 Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2016-2027)
8.3 Asia-Pacific HER2-Positive Breast Cancer Market Size by Application
8.3.1 Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2016-2021)
8.3.2 Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2022-2027)
8.3.3 Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2016-2027)
8.4 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region
8.4.1 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2016-2021)
8.4.2 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America HER2-Positive Breast Cancer Market Size (2016-2027)
9.2 Latin America HER2-Positive Breast Cancer Market Size by Type
9.2.1 Latin America HER2-Positive Breast Cancer Market Size by Type (2016-2021)
9.2.2 Latin America HER2-Positive Breast Cancer Market Size by Type (2022-2027)
9.2.3 Latin America HER2-Positive Breast Cancer Market Size by Type (2016-2027)
9.3 Latin America HER2-Positive Breast Cancer Market Size by Application
9.3.1 Latin America HER2-Positive Breast Cancer Market Size by Application (2016-2021)
9.3.2 Latin America HER2-Positive Breast Cancer Market Size by Application (2022-2027)
9.3.3 Latin America HER2-Positive Breast Cancer Market Size by Application (2016-2027)
9.4 Latin America HER2-Positive Breast Cancer Market Size by Country
9.4.1 Latin America HER2-Positive Breast Cancer Market Size by Country (2016-2021)
9.4.2 Latin America HER2-Positive Breast Cancer Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HER2-Positive Breast Cancer Market Size (2016-2027)
10.2 Middle East & Africa HER2-Positive Breast Cancer Market Size by Type
10.2.1 Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2016-2021)
10.2.2 Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2022-2027)
10.2.3 Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2016-2027)
10.3 Middle East & Africa HER2-Positive Breast Cancer Market Size by Application
10.3.1 Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2016-2021)
10.3.2 Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2022-2027)
10.3.3 Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2016-2027)
10.4 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country
10.4.1 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2016-2021)
10.4.2 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer (Pharmacia and Upjohn Company)
11.1.1 Pfizer (Pharmacia and Upjohn Company) Company Details
11.1.2 Pfizer (Pharmacia and Upjohn Company) Business Overview
11.1.3 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Introduction
11.1.4 Pfizer (Pharmacia and Upjohn Company) Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.1.5 Pfizer (Pharmacia and Upjohn Company) Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis HER2-Positive Breast Cancer Introduction
11.2.4 Novartis Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 AstraZeneca Pharmaceuticals
11.3.1 AstraZeneca Pharmaceuticals Company Details
11.3.2 AstraZeneca Pharmaceuticals Business Overview
11.3.3 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.3.4 AstraZeneca Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.3.5 AstraZeneca Pharmaceuticals Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Details
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly HER2-Positive Breast Cancer Introduction
11.4.4 Eli Lilly Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.4.5 Eli Lilly Recent Development
11.5 Roche Group
11.5.1 Roche Group Company Details
11.5.2 Roche Group Business Overview
11.5.3 Roche Group HER2-Positive Breast Cancer Introduction
11.5.4 Roche Group Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.5.5 Roche Group Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck HER2-Positive Breast Cancer Introduction
11.6.4 Merck Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.6.5 Merck Recent Development
11.7 Jiangsu HengRui Medicine
11.7.1 Jiangsu HengRui Medicine Company Details
11.7.2 Jiangsu HengRui Medicine Business Overview
11.7.3 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Introduction
11.7.4 Jiangsu HengRui Medicine Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.7.5 Jiangsu HengRui Medicine Recent Development
11.8 Odonate Therapeutics
11.8.1 Odonate Therapeutics Company Details
11.8.2 Odonate Therapeutics Business Overview
11.8.3 Odonate Therapeutics HER2-Positive Breast Cancer Introduction
11.8.4 Odonate Therapeutics Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.8.5 Odonate Therapeutics Recent Development
11.9 Radius Pharmaceuticals
11.9.1 Radius Pharmaceuticals Company Details
11.9.2 Radius Pharmaceuticals Business Overview
11.9.3 Radius Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.9.4 Radius Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.9.5 Radius Pharmaceuticals Recent Development
11.10 Immunomedics
11.10.1 Immunomedics Company Details
11.10.2 Immunomedics Business Overview
11.10.3 Immunomedics HER2-Positive Breast Cancer Introduction
11.10.4 Immunomedics Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.10.5 Immunomedics Recent Development
11.11 Syndax Pharmaceuticals
11.11.1 Syndax Pharmaceuticals Company Details
11.11.2 Syndax Pharmaceuticals Business Overview
11.11.3 Syndax Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.11.4 Syndax Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.11.5 Syndax Pharmaceuticals Recent Development
11.12 Bayer
11.12.1 Bayer Company Details
11.12.2 Bayer Business Overview
11.12.3 Bayer HER2-Positive Breast Cancer Introduction
11.12.4 Bayer Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.12.5 Bayer Recent Development
11.13 Eagle Pharmaceuticals
11.13.1 Eagle Pharmaceuticals Company Details
11.13.2 Eagle Pharmaceuticals Business Overview
11.13.3 Eagle Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.13.4 Eagle Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.13.5 Eagle Pharmaceuticals Recent Development
11.14 Merrimack Pharmaceuticals
11.14.1 Merrimack Pharmaceuticals Company Details
11.14.2 Merrimack Pharmaceuticals Business Overview
11.14.3 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.14.4 Merrimack Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.14.5 Merrimack Pharmaceuticals Recent Development
11.15 GlaxoSmithKline
11.15.1 GlaxoSmithKline Company Details
11.15.2 GlaxoSmithKline Business Overview
11.15.3 GlaxoSmithKline HER2-Positive Breast Cancer Introduction
11.15.4 GlaxoSmithKline Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.15.5 GlaxoSmithKline Recent Development
11.16 Millennium Pharmaceuticals
11.16.1 Millennium Pharmaceuticals Company Details
11.16.2 Millennium Pharmaceuticals Business Overview
11.16.3 Millennium Pharmaceuticals HER2-Positive Breast Cancer Introduction
11.16.4 Millennium Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021)
11.16.5 Millennium Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global HER2-Positive Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Grifola Frondosa
Table 3. Key Players of Surgery
Table 4. Key Players of Radiation and Chemotherapy
Table 5. Key Players of Endocrine Therapy
Table 6. Key Players of Molecular Targeted Therapy
Table 7. Global HER2-Positive Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global HER2-Positive Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global HER2-Positive Breast Cancer Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global HER2-Positive Breast Cancer Market Share by Regions (2016-2021)
Table 11. Global HER2-Positive Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global HER2-Positive Breast Cancer Market Share by Regions (2022-2027)
Table 13. HER2-Positive Breast Cancer Market Trends
Table 14. HER2-Positive Breast Cancer Market Drivers
Table 15. HER2-Positive Breast Cancer Market Challenges
Table 16. HER2-Positive Breast Cancer Market Restraints
Table 17. Global HER2-Positive Breast Cancer Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global HER2-Positive Breast Cancer Market Share by Players (2016-2021)
Table 19. Global Top HER2-Positive Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-Positive Breast Cancer as of 2020)
Table 20. Ranking of Global Top HER2-Positive Breast Cancer Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by HER2-Positive Breast Cancer Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players HER2-Positive Breast Cancer Product Solution and Service
Table 24. Date of Enter into HER2-Positive Breast Cancer Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 27. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2016-2021)
Table 28. Global HER2-Positive Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global HER2-Positive Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global HER2-Positive Breast Cancer Revenue Market Share by Application (2016-2021)
Table 32. Global HER2-Positive Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global HER2-Positive Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 35. North America HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 37. North America HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America HER2-Positive Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America HER2-Positive Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe HER2-Positive Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe HER2-Positive Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific HER2-Positive Breast Cancer Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America HER2-Positive Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America HER2-Positive Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa HER2-Positive Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa HER2-Positive Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa HER2-Positive Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 64. Pfizer (Pharmacia and Upjohn Company) Company Details
Table 65. Pfizer (Pharmacia and Upjohn Company) Business Overview
Table 66. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product
Table 67. Pfizer (Pharmacia and Upjohn Company) Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 68. Pfizer (Pharmacia and Upjohn Company) Recent Development
Table 69. Novartis Company Details
Table 70. Novartis Business Overview
Table 71. Novartis HER2-Positive Breast Cancer Product
Table 72. Novartis Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 73. Novartis Recent Development
Table 74. AstraZeneca Pharmaceuticals Company Details
Table 75. AstraZeneca Pharmaceuticals Business Overview
Table 76. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product
Table 77. AstraZeneca Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 78. AstraZeneca Pharmaceuticals Recent Development
Table 79. Eli Lilly Company Details
Table 80. Eli Lilly Business Overview
Table 81. Eli Lilly HER2-Positive Breast Cancer Product
Table 82. Eli Lilly Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 83. Eli Lilly Recent Development
Table 84. Roche Group Company Details
Table 85. Roche Group Business Overview
Table 86. Roche Group HER2-Positive Breast Cancer Product
Table 87. Roche Group Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 88. Roche Group Recent Development
Table 89. Merck Company Details
Table 90. Merck Business Overview
Table 91. Merck HER2-Positive Breast Cancer Product
Table 92. Merck Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 93. Merck Recent Development
Table 94. Jiangsu HengRui Medicine Company Details
Table 95. Jiangsu HengRui Medicine Business Overview
Table 96. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product
Table 97. Jiangsu HengRui Medicine Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 98. Jiangsu HengRui Medicine Recent Development
Table 99. Odonate Therapeutics Company Details
Table 100. Odonate Therapeutics Business Overview
Table 101. Odonate Therapeutics Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 102. Odonate Therapeutics Recent Development
Table 103. Radius Pharmaceuticals Company Details
Table 104. Radius Pharmaceuticals Business Overview
Table 105. Radius Pharmaceuticals HER2-Positive Breast Cancer Product
Table 106. Radius Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 107. Radius Pharmaceuticals Recent Development
Table 108. Immunomedics Company Details
Table 109. Immunomedics Business Overview
Table 110. Immunomedics HER2-Positive Breast Cancer Product
Table 111. Immunomedics Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 112. Immunomedics Recent Development
Table 113. Syndax Pharmaceuticals Company Details
Table 114. Syndax Pharmaceuticals Business Overview
Table 115. Syndax Pharmaceuticals HER2-Positive Breast Cancer Product
Table 116. Syndax Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 117. Syndax Pharmaceuticals Recent Development
Table 118. Bayer Company Details
Table 119. Bayer Business Overview
Table 120. Bayer HER2-Positive Breast Cancer Product
Table 121. Bayer Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 122. Bayer Recent Development
Table 123. Eagle Pharmaceuticals Company Details
Table 124. Eagle Pharmaceuticals Business Overview
Table 125. Eagle Pharmaceuticals HER2-Positive Breast Cancer Product
Table 126. Eagle Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 127. Eagle Pharmaceuticals Recent Development
Table 128. Merrimack Pharmaceuticals Company Details
Table 129. Merrimack Pharmaceuticals Business Overview
Table 130. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product
Table 131. Merrimack Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 132. Merrimack Pharmaceuticals Recent Development
Table 133. GlaxoSmithKline Company Details
Table 134. GlaxoSmithKline Business Overview
Table 135. GlaxoSmithKline HER2-Positive Breast Cancer Product
Table 136. GlaxoSmithKline Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 137. GlaxoSmithKline Recent Development
Table 138. Millennium Pharmaceuticals Company Details
Table 139. Millennium Pharmaceuticals Business Overview
Table 140. Millennium Pharmaceuticals HER2-Positive Breast Cancer Product
Table 141. Millennium Pharmaceuticals Revenue in HER2-Positive Breast Cancer Business (2016-2021) & (US$ Million)
Table 142. Millennium Pharmaceuticals Recent Development
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HER2-Positive Breast Cancer Market Share by Type: 2020 VS 2027
Figure 2. Grifola Frondosa Features
Figure 3. Surgery Features
Figure 4. Radiation and Chemotherapy Features
Figure 5. Endocrine Therapy Features
Figure 6. Molecular Targeted Therapy Features
Figure 7. Global HER2-Positive Breast Cancer Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Specialist Clinic Case Studies
Figure 10. Biotechnology and Pharmaceutical Companies Case Studies
Figure 11. Research and Academic Institutions Case Studies
Figure 12. Other Case Studies
Figure 13. HER2-Positive Breast Cancer Report Years Considered
Figure 14. Global HER2-Positive Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global HER2-Positive Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global HER2-Positive Breast Cancer Market Share by Regions: 2020 VS 2027
Figure 17. Global HER2-Positive Breast Cancer Market Share by Regions (2022-2027)
Figure 18. Global HER2-Positive Breast Cancer Market Share by Players in 2020
Figure 19. Global Top HER2-Positive Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER2-Positive Breast Cancer as of 2020
Figure 20. The Top 10 and 5 Players Market Share by HER2-Positive Breast Cancer Revenue in 2020
Figure 21. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2016-2021)
Figure 22. Global HER2-Positive Breast Cancer Revenue Market Share by Type (2022-2027)
Figure 23. North America HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America HER2-Positive Breast Cancer Market Share by Type (2016-2027)
Figure 25. North America HER2-Positive Breast Cancer Market Share by Application (2016-2027)
Figure 26. North America HER2-Positive Breast Cancer Market Share by Country (2016-2027)
Figure 27. United States HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe HER2-Positive Breast Cancer Market Share by Type (2016-2027)
Figure 31. Europe HER2-Positive Breast Cancer Market Share by Application (2016-2027)
Figure 32. Europe HER2-Positive Breast Cancer Market Share by Country (2016-2027)
Figure 33. Germany HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific HER2-Positive Breast Cancer Market Share by Type (2016-2027)
Figure 41. Asia-Pacific HER2-Positive Breast Cancer Market Share by Application (2016-2027)
Figure 42. Asia-Pacific HER2-Positive Breast Cancer Market Share by Region (2016-2027)
Figure 43. China HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America HER2-Positive Breast Cancer Market Share by Type (2016-2027)
Figure 51. Latin America HER2-Positive Breast Cancer Market Share by Application (2016-2027)
Figure 52. Latin America HER2-Positive Breast Cancer Market Share by Country (2016-2027)
Figure 53. Mexico HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa HER2-Positive Breast Cancer Market Share by Type (2016-2027)
Figure 57. Middle East & Africa HER2-Positive Breast Cancer Market Share by Application (2016-2027)
Figure 58. Middle East & Africa HER2-Positive Breast Cancer Market Share by Country (2016-2027)
Figure 59. Turkey HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE HER2-Positive Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Pfizer (Pharmacia and Upjohn Company) Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 63. Novartis Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 64. AstraZeneca Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 65. Eli Lilly Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 66. Roche Group Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 67. Merck Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 68. Jiangsu HengRui Medicine Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 69. Odonate Therapeutics Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 70. Radius Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 71. Immunomedics Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 72. Syndax Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 73. Bayer Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 74. Eagle Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 75. Merrimack Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 76. GlaxoSmithKline Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 77. Millennium Pharmaceuticals Revenue Growth Rate in HER2-Positive Breast Cancer Business (2016-2021)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
世界のHER2陽性進行性乳がん用モノクローナル抗体（mAb）市場規模・現状・予測（2021年-2027年） These antibodies are used to treat metastatic (spread) breast cancer. It is effective against tumors that overexpress the HER2/neu protein. Market Analysis and Insights: Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market The global Mono-Antibody (mAb) for HER2-Positive Advanc…- 世界のHER2陰性乳がん治療市場規模・現状・予測（2021年-2027年） HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein. Market Analysis and Insights: Global HER2-negative breast ca…
- 世界のHER2陰性乳がん治療市場規模・現状・予測（2021年-2027年） HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein. Market Analysis and Insights: Global HER2-negative breast ca…
- 世界のHR+/HER2-乳がん市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global HR+/HER2- Breast Cancer Market The global HR+/HER2- Breast Cancer market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the re…
- 世界の乳がん治療市場規模・現状・予測（2021年-2027年） Breast cancer is the one of the most prevalent cancer and among the leading cause of death in cancer patients. According, to WHO 2013 report 50800 women died of breast cancer in 2011. Metastatic breast cancer is an advanced stage of breast cancer. It involves cases in which breast cancer has spread …